The second article in this series, Standards for Clinical Trials in Male and Female Sexual Dysfunction, focuses on measurement of patient-reported outcomes (PROs). Together with the design of appropriate phase I to phase IV clinical trials, the development, validation, choice, and implementation of valid PRO measurements-the focus of the present article-form the foundation of research on treatments for male and female sexual dysfunctions. PRO measurements are assessments of any aspect of a patient's health status that come directly from the patient (ie, without the interpretation of the patient's responses by a physician or anyone else). PROs are essential for assessing male and female sexual dysfunction and treatment response, including symptom frequency and severity, personal distress, satisfaction, and other measurements of sexual and general health-related quality of life. Although there are some relatively objective measurements of sexual dysfunction (ie, intravaginal ejaculatory latency time, frequency of sexual activity, etc), these measurements do not comprehensively assess the occurrence and extent of sexual dysfunction or treatment on the patient's symptoms, functioning, and well-being. Data generated by a PRO instrument can provide evidence of a treatment benefit from the patient's perspective.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jsxm.2016.08.015DOI Listing

Publication Analysis

Top Keywords

sexual dysfunction
20
male female
16
female sexual
16
clinical trials
12
standards clinical
8
trials male
8
sexual
8
dysfunction treatment
8
measurements sexual
8
dysfunction
5

Similar Publications

Background: Chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) are prevalent disease complications in people with cystic fibrosis. These understudied comorbidities significantly impact quality of life. The impact of highly effective modulator therapy (HEMT) in young children with cystic fibrosis (YCwCF) on these disease complications is unknown.

View Article and Find Full Text PDF

Utilizing network pharmacology and molecular docking, we evaluated the possible pharmacological mechanism of Danggui Sini Decoction (DGSND) for treating erectile dysfunction (ED). DGSND's chemical components and targets were found utilizing the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). Disease-related genes associated with ED were identified through GeneCards, OMIM, TTD, DrugBank, and DisGeNET databases.

View Article and Find Full Text PDF

Background: In Asian countries, discussing sex-related issues remains a taboo. Sexual dysfunction is not even considered a serious disorder in Pakistan.

Aim: To explore sexual dysfunction and marital satisfaction within the Pakistani context to develop supportive intervention programs.

View Article and Find Full Text PDF

Management of female para-urethral cyst with dyspareunia: a case report.

J Med Case Rep

January 2025

Department of Urology, SRM Institute of Science and Technology, SRM Nagar, Chengalpattu, Kattankulathur, Tamilnadu, 603203, India.

Background: The diagnosis and management of female genital conditions (Rodriguez et al. in Clin Anat 34(1):103-107, 2020. https://doi.

View Article and Find Full Text PDF

Background: Sexual dysfunction (SD) is a complication of poorly managed diabetes mellitus (DM). To prevent SD, patients should develop sexual health literacy (SHL).

Objective: This study investigated the relationship between SHL and SD in women with DM.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!